The April and YTD performances of the psychedelic drug stocks we track in our index, vary pretty widely from company to company, but almost universally are expected to rise substantially.

The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts.

Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 - DOWN 73% vs. 2021 - but perhaps some of them will bounce back with major - dare I say "multi-bagger" - returns in 2023.

A review of Cybin Inc.'s latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock over the next 12 months.

Cannabis, psychedelic and plant-based food stocks were extremely oversold in 2022 but perhaps some will bounce back with "multi-bagger" returns in 2023. Year-to-date our "Multi-bagger" Portfolio is +15.4% versus only +3.4% for the S&P 500.